Microbot Medical exits clinical stage with FDA clearance, doubles headcount for commercial launch

Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 25, 2025 · ~1 min read

Key Changes

• high

  FDA granted 510(k) clearance for LIBERTY robotic surgical system in September 2025; limited market release began November 2025 with first hospital adoptions at Emory and Tampa General; full commercial launch planned April 2026.

  Business: FDA clearance and market release verify on EDGAR →
• high

  Company raised $93 million in 2025, more than doubling cumulative capital to $168 million; working capital surged from $3.4 million to $76.4 million, providing substantial runway for commercialization.

  MD&A: Capital raised and working capital verify on EDGAR →
• high

  Headcount doubled from 21 to 43 employees, with U.S.-based staff expanding from 6 to 24 to support commercial operations; SG&A expenses rose $3.5 million (70%) driven by sales/marketing hires and commercialization activities.

  Business: Employee headcount / MD&A: SG&A expenses verify on EDGAR →